Site-specific eukaryotic genome editing with CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) systems has quickly become a commonplace amongst researchers pursuing a wide variety of biological questions. Users most often employ the Cas9 protein derived from Streptococcus pyogenes in a complex with an easily reprogrammed guide RNA (gRNA). These components are introduced into cells, and through a base pairing with a complementary region of the double-stranded DNA (dsDNA) genome, the enzyme cleaves both strands to generate a double-strand break (DSB). Subsequent repair leads to either random insertion or deletion events (indels) or the incorporation of experimenter-provided DNA at the site of the break.
Introduction
fThe CRISPR-Cas9 system allows scientists to alter targeted regions of any genome 1 . This quick and inexpensive technology has revolutionized basic research and promises to make a profound impact on the development of personalized disease therapies, precision agriculture, and beyond 2 . CRISPR editing is a democratizing tool and implementing the system in a new laboratory requires no particular expertise in genome engineering, just basic molecular biology skills. Researchers can now study previously intractable organisms with a few alternative means for genetic manipulation 3, 4 . Cell repair machinery fixes the DSB by one of at least two routes: via the error-prone non-homologous end-joining (NHEJ) pathway or the homology-directed repair (HDR), which seamlessly incorporates DNA containing 'arms' of homology to either side of the break. The former repair pathway typically leads to indel formation and consequent gene disruption, while the latter allows experimenters to insert or change DNA sequences 1 .
The editing efficiency and accuracy depend on the means by which Cas9 and gRNA enter into the cell. These components may be delivered to cultured cells, embryos, or organisms in the form of nucleic acids or as a preassembled RNP complex 13, 14, 15 . Common nucleic acid-based delivery methods include the viral transduction, transfection, or electroporation of mRNA or plasmid DNA. Cas9 protein and guide RNA are then produced within the cell and they associate to form a complex.
The direct delivery of RNP requires the separate purification of the Cas9 protein and guide RNA. This can be done in-house, or the protein and sgRNA can be purchased from one of several commercial vendors. Once acquired, the Cas9 and gRNA are mixed to form the enzymaticallycompetent RNP complex and introduced to cells by direct injection into fertilized eggs/embryos, lipid-based transfection 16 , or electroporation. The first report of RNP editing involved injection into C. elegans gonads 17 . Microinjection is still the preferred means of introducing RNP into embryos and whole organisms, though effective electroporation has been demonstrated in mouse 18, 19 and rat 20 embryos. We describe protocols for directly injecting RNP into C. elegans gonads and P. hawaiensis embryos and recommend a specialized type of electroporation to deliver RNP when editing primary human cells. This method, nucleofection, involves optimized electroporation programs and cell type-specific solutions and allows the RNP to enter both the cytoplasm and the nucleus 21 .
Genome editing with RNP offers several distinct advantages. Because the protein and RNA components are pre-assembled, and quality can be ensured prior to delivery, RNP editing avoids many pitfalls associated with the nucleic acid-based delivery. Namely, there is no risk of Cas9-encoding DNA integration into the host genome, mRNA is never exposed for degradation, and it circumvents problems with in vivo gRNA or protein expression, folding, and association 22, 23 . Further, using RNP leads to lower toxicity and far fewer off-target events than the plasmid-based expression, a result of the RNP's shorter half-life inside the cell 24, 25, 26, 27 . Finally, RNP editing demonstrably leads to high editing rates in a variety of human cell lines, primary cells such as fibroblasts, embryonic stem cells (ESCs), induced pluripotent stem cells (iSPCs), HSPCs, and T cells 16, 24, 25, 26, 27, 28, 29 ; in invertebrates including C. elegans, P. hawaiensis, and fruit flies 3, 17, 30 ; in vertebrate species like zebrafish, mice, and rats 31, 32 ; in plant species including Arabidopsis, tobacco, lettuce, rice, grapevine, apple, maize, and wheat 33, 34, 35, 36 ; and in Chlamydomonas, Penicillium, and Candida species 37, 38, 39 . The frequency of indel formation can be higher when using RNP compared to the plasmid delivery, and HDR-mediated DNA insertion can be easier to achieve 25, 27, 29 .
The protocol described here uses the Cas9 RNP and is an effective, readily adaptable technique that is straightforward to apply to a wide variety of biological systems 40, 41 , especially in cells that are otherwise difficult to work with and in organisms without well-established systems for precise genetic manipulation. We start by describing how to design, obtain, and assemble the Cas9 RNP before covering its use across different model cell types and organisms. Hematopoietic stem/progenitor cells (HSPCs) and T cells are edited using the same method, nucleofection, so they are covered together in steps 2 and 3 of this protocol. Editing procedures for C. elegans are described in steps 4 and 5, and P. hawaiensis editing is covered in steps 6 and 7. Finally, since the success of a gene-editing experiment in any organism may be assessed by genotype sequencing, substeps describing possible analysis methods for all the cells and organisms described in the protocol are outlined in step 8.
Protocol

RNP Assembly
1. Design the experiment well in advance, acquiring all the RNA, DNA, and protein components ahead of time. As a first pass, try one of the positive controls listed in Table 1 and use the commercial reagents described in the . NOTE: Once assembled as described in the subsequent steps, RNPs prepared in advance may be stored at -80 °C.
1. After choosing which gene to target, use one of the free online tools to design an optimal gRNA 44, 45, 46, 47, 48 . Be sure to target an exon if hoping to generate a knockout. Note: These tools will help to identify a target site with an adjacent S. pyogenes PAM sequence, high-quality score, and low off-target score. 2. Purify the S. pyogenes Cas9 protein through published methods 8 , or purchase it from a commercial vendor. 3. Prepare a typical Cas9 buffer for the RNA dilution, RNP preparation, and protein storage, which contains 20 mM of HEPES pH 7.5, 150 mM of KCl, 10% glycerol, and 1 mM of TCEP. Always use nuclease-free water in buffers that will be used to resuspend or dilute RNA to prevent degradation. 4. Produce the guide RNA (tracrRNA and crRNA or sgRNA) through an in vitro transcription using published methods, or purchase it from a nucleic acid synthesis company NOTE: The efficiency of a Cas9-mediated DSB-templated repair is proportional to the concentration of the dsDNA repair construct; thus, the higher the concentration of the repair template, the more efficient the templated repair. However, an injection of mixes containing greater than 350 ng/µL of dsDNA has been shown to reduce the viability of the injected worms. Thus, it is best to use up to, but no more than 350 ng/µL of dsDNA in the mix to maximize the repair efficiency while minimizing its lethality. 1. Add multiple crRNAs to target multiple loci simultaneously, as needed for the co-CRISPR/co-conversion screening approach described in step 5.4. When adding more than one crRNA, add each sequentially to the master mix. NOTE: The amount of each crRNA does not need to be the same, and even doubling the total concentration of crRNAs in the master mix without changing the concentration of Cas9 does not appear to interfere with the frequency of mutagenesis at a specific locus. Examples are described in detail in Paix et al. 
Cell Culture and Preparation
NOTE: Perform steps 2.1.1 to 3.3.3 in a biological safety cabinet.
Purchase cryopreserved human mobilized peripheral blood CD34
+ HSPCs from a vendor.
1. Thaw ~1 x10 6 HSPCs in a 37 °C water bath for 3 min and transfer them to a 15 mL conical tube. Add 10 mL of a serum-free expansion medium from a commercial source and spin the mixture at 100 x g for 10 min. Remove the supernatant and resuspend the cells in 2 mL of supplemented SFEM. Plate the cells in 6-well plates and culture them in a 37 °C incubator for 24-48 h prior to the RNP electroporation. 2. Count the cells with a hemocytometer and transfer the total number of HSPCs needed (150,000-200,000 HSPCs per cuvette to be electroporated) to a centrifuge tube. 3. Spin the tube at 100 x g for 10 min to pellet the cells.
Purchase human primary CD4
+ T cells from a vendor or isolate them from human whole blood by the density gradient centrifugation 29 .
1.
Prior to the T cell activation, pre-coat 48-well culture plates with αCD3 (UCHT1) and αCD28 (CD28.2). Coat the plates with 500 µL of 10 µg/mL αCD3 and 10 µg/mL αCD28 in PBS for at least 2 h at 37 °C. NOTE: For some loci, NHEJ can be achieved without pre-stimulation, but including this step maximizes its efficiency. 2. Culture the T cells for 48 h at 37 °C on αCD3/αCD28 antibody-bound plates in a RPMI complete medium [RPMI-1640 supplemented with 5 mM of HEPES, 2 mM of commercial alternative to L-Glutamine, 50 µg/mL of penicillin/streptomycin, 50 µM of 2-mercaptoethanol, 5 mM of non-essential amino acids, 5 mM of sodium pyruvate, and 10% (vol/vol) FBS]. Culture the T cells at a density of 2,000,000 T cells in 500 µL of media per well of a 48-well plate. 3. Count the T cells using a hemocytometer and transfer the total number of T cells necessary for the electroporation experiment (100,000-1,000,000 T cells per cuvette to be electroporated) to a centrifuge tube. agarose solution onto the slide. Quickly flatten the agarose drop by placing another coverslip on top. Allow the agarose to solidify and then remove one of the coverslips. 3. Leave the agarose-coated coverslip face-up on a tabletop overnight to dry. After 24 h, store the agarose pads in a clean, dry container.
NOTE: These can be used indefinitely.
2. Pull the microinjection needles: using borosilicate glass capillaries with filaments (outer diameter 1.0 mm and inner diameter 0.58 mm), pull the needles based on Mello and Fire 57 and other resources 58 . The needles can be used immediately or can be stored in a clean, dry container, braced by clay supports. 3. For the maintenance of the worms, prepare a Nematode Growth Media (NGM) agar poured into Petri plates and spotted with OP50 bacteria (for protocols on standard C. elegans maintenance and recipes for growth media, see Stiernagle 59 ). 4. Stage the worms for microinjection: 12-24 h prior to the microinjection, pick L4-staged hermaphrodites to a new NG-agar plate with OP50 bacteria and incubate them overnight at 20 °C. For each Cas9 target/injection mix, pick ~30 worms to the plate. 5. Day of microinjection: Load the pulled microinjection needle with the RNP solution supernatant prepared in step 1.5.
1. Pipette the supernatant from step 1.5.4 into a pulled capillary pipette and backfill the solution from the capillary pipette into the prepared microinjection needle (generally loading less than 0.1 µL).
6. Mount the loaded needle onto the microinjection apparatus attached to a micromanipulator. Set the injection apparatus pressure to 250 kPa and the balance pressure to 25 kPa. ). 1. Make dissection needles by threading a bent piece of tungsten wire approximately 0.5 in in length into the end of an insulin needle.
Sharpen the needle in sodium hydroxide under a current. Use a 1 mL syringe as the handle of the dissection needle. 2. Fill one well of a 3-well glass dish halfway with a freshly-made solution of 9 parts PEM Buffer (0.1 M of PIPES pH 6.95, 2 mM of EGTA, 1 mM of MgSO 4 ), 1-part 10x PBS, and 1 part 32% PFA. Place 3-5 embryos into the dish and poke a small hole into each embryo, using a sharp tungsten needle to poke and a slightly dulled one to stabilize, allowing the yolk to flow out and the fixative to run in. 3. Using a pair of sharpened tungsten needles, gently tease away the outer two membranes surrounding the Parhyale embryo. Dissect them in fixative to make the embryos more robust but work quickly to keep the membrane from becoming fixed to the embryo, which makes membrane removal more difficult. Allow the embryos to fix for a total of 15-20 min. for antibody staining or 40-50 min for in situ hybridization. 6 . Image live hatchlings and analyze them for morphological and behavioral phenotypes or fix and stain them for more detailed analyses. Raise the hatchlings to sexual maturity in 2-3 months to establish knockout and transgenic lines (see Kontarakis and Pavlopoulos 75 for hatchling care and other useful details).
Assessing Editing Outcomes
1. If applicable, look for a visual or functional phenotype in the edited cells or organisms. NOTE: This process will vary widely by application, and some examples are described at the end of their relevant protocol steps above. After correcting the sickle cell mutation in HSPCs, analyze the hemoglobin production by differentiated erythroblasts using HPLC ( Figure 1A) . A knockout of the IL-2 receptor gene in T cells can be confirmed by surface staining and flow cytometry ( Figure 1B) . To assess C. elegans and P. hawaiensis phenotypes, observe the animal morphology and behavior under a light or fluorescent microscope (Figures 1C and 1D ). 2. To determine the efficiency and type of the genomic edits generated, lyse the pools of edited cells and extract their genomic DNA using a commercial extraction kit 21 .
For a quick estimation of indel formation, PCR-amplify at least 200 base pairs around the cut site and perform a T7 endonuclease1
(T7E1) 76 or surveyor (CEL-1 nuclease) assay 77 .
1.
If an indel formation at the Cas9-cut site or successful HDR will create or remove a known restriction site, consider using a restriction enzyme digestion to estimate the editing efficiency 6 . The restriction fragment length polymorphism (RFLP) assay can be a convenient way to check the efficiency if it happens to be available. , as shown in Figure 2B . 3. For a full quantification and sequences of editing outcomes, perform deep sequencing 27, 54 , as depicted in Figure 2C . 4. To assess a particular set of off-target changes, PCR-amplify the predicted off-target sites and send them for NGS. To enable the detection of chromosomal translocations, perform GUIDE-seq 79 or high-throughput, genome-wide translocation sequencing (HTGTS) 80 . For a complete picture of the off-target edits in a clonal population, perform whole-genome sequencing (WGS) 81, 82, 83 . NOTE: There are a variety of methods for quantifying on-and off-target genome edits, explained further in various review articles 84, 85, 86 .
Representative Results
These experiments show how pre-assembled Cas9 RNP can be used to manipulate the genomes of primary cells and whole organisms. Researchers purify or purchase Cas9 protein and sgRNA, combine the two components to pre-form the complex, and introduce the RNP into their cells or organism of interest. After allowing enough time for editing to occur and for offspring of the next generation to be born (if applicable), check for phenotypes and/or collect cells for genotyping. Phenotypes may be observed via functional assays, expression assays, visualization (by eye or with microscopy), or other methods, depending on the experiment.
For example, HSPCs that have been edited to correct the β-globin mutation that causes sickle cell disease can be differentiated into erythrocytes and assayed for the production of healthy or sickle hemoglobin 27, 87 ( Figure 1A) . T cells edited to knock out the high-affinity IL-2 receptor gene, CD25 (IL2RA), can be analyzed by surface staining and flow cytometry 88 , and functionally analyzed to detect a signaling response to IL-2 stimulation (Figure 1B) . T cells can also be reprogrammed in many clinically important ways that require assessment of different phenotypes, including the efficacy of HIV infection 89 and the in vivo antitumor efficacy of CAR-T cells . HDR at the dpy-10 reference gene using a ssODN repair template results in an easily-scored dominant dpy-10 gain-of-function mutation. Heterozygous F 1 dpy-10(gof) animals are roller (Rol) and homozygous dpy-10(gof) animals are dumpy (Dpy). The presence of the phenotype indicates that Cas9 editing occurred in these animals and improves the odds of identifying an editing event at the second locus in the Rol or Dpy F 1 animals. A successful editing experiment should result in 33-50% of injected P 0 worms yielding 20 or more F 1 offspring that are Rol or Dpy 90 . It is then possible to choose non-Rol animals to return dpy-10 to wildtype and select for the homozygous edit of interest. As a rule of thumb, the concentration of the crRNA targeting the co-CRISPR reference gene should be half that of the crRNA targeting the gene of interest. If an edit in the gene of interest is not recovered, the ratios of the two CRISPR RNAs can be adjusted to increase the likelihood of recovering the desired mutation. For instance, increasing the amount of crRNA for the gene of interest relative to the reference gene crRNA will increase the percentage of worms possessing edits in the gene of interest within the population of worms that also possess edits at the reference gene locus. Co-conversion frequencies vary, but the rates are typically 20-60%, often yielding homozygous edits in the F 1 generation ( Figure 1C) . P. hawaiensis hatchlings that have been edited to knock out the Abdominal-B gene (Abd-B) display clear morphological abnormalities 3 ( Figure   1D ). This gene is required for correct abdominal patterning, and its disruption results in thoracic-type jumping and walking legs replacing the swimming and anchor legs that are usually present on the abdomen.
Determining genome editing outcomes at the genotypic level requires either sequencing or an in vitro assay that detects sequence changes. Here, we show representative sequencing data from our model cell types and organisms, highlighting different approaches to editing quantification. Note that the figure labels are generalized because all methods shown here can be applied to any biological system.
Sequencing-based approaches vary in technical complexity and depth of results. For clonal edited populations or easily-separable individual organisms, edited individuals can be sequenced following genomic DNA extraction. Standard Sanger sequencing results will reveal the sequence change at the Cas9-cut site in a given individual, with hypothetical frameshifts that would disrupt its function (Figure 2A) . The online tool used for sequencing is another Sanger sequencing-based approach that can be applied to mixed populations rather than individual mutants 78 . Sequences are analyzed with an online tool that can approximate overall editing efficiency as well as predominant sequence outcomes. The representative data are shown in Figure 2B .
The most thorough sequencing method described here is deep sequencing (sometimes referred to as high-throughput or next-generation sequencing). This method provides DNA sequences from individual genomes in a mixed population. Such data can be illustrated in a variety of ways. Here, we have classified individual sequencing reads from edited cells based on the editing outcome ( Figure 2C ). Most cells are edited via the NHEJ pathway, which typically results in gene disruption. In others, the target gene has been swapped out for an alternate version via HDR 27 . Table 1 : Positive controls for preliminary genome editing experiments. This table shows the key information needed to perform a firsttime genome editing experiment in each of the cells and organisms described in this protocol. Following these parameters is likely to yield a successful result that can be used to test the protocol or as a baseline for comparison once the experimenter is targeting a gene of their own interest. F: forward, R: reverse, HDR: homology-directed repair. Please click here to download this table. 
Discussion
Establishing a robust genome editing protocol in a cell line or organism of interest requires the optimization and empirical testing of several key parameters, discussed in this section. Trying a few variations of the general approaches presented here is highly encouraged. The key limitation of this protocol is that applying these methods to other cells or organisms may lead to a different outcome depending on the species studied, and an experimental design that leads to a high-efficiency gene knockout may not promote DNA insertion. Thus, we recommend starting with the methods presented here and troubleshooting as described below.
Troubleshooting genome editing reagent quality:
Generating or purchasing high-quality reagents is a critical step in any genome editing protocol. Cas9 protein can be purified in the lab or purchased commercially. Many protocols note a final concentration for Cas9 in RNP recipes, but the optimal gene editing activity will depend on the specific activity of any individual Cas9 protein preparation, which varies depending on the source. Once the protocol presented here is working, consider optimizing the amount of RNP used by titrating Cas9 levels to establish an optimal concentration: one that provides highly specific target DNA cleavage without unnecessary off-target cleavage caused by excessive Cas9 40 .
Guide RNA purity and homogeneity can also be determinants of genome editing success 22 . Purchased sgRNAs or separate crRNA and tracrRNA components are generally high-quality reagents and a variety of chemical modifications are available to combat problems with RNA degradation or to imbue additional features to the RNP 91 . While chemically-modified gRNAs may not be necessary for standard genome editing experiments, some groups have observed much higher editing efficiencies with such reagents, so they may be worth trying after mastering the process and/or when gRNA degradation appears to be an issue 22, 91 . In vitro transcription and subsequent gel purification is an inexpensive alternative, which may be sufficient for routine genome editing experiments 17, 21, 49, 50 . Further, several approaches that are commonly applied to produce homogenous gRNA populations in vivo, including ribozyme-and tRNA-based excision of individual guides, may be extended to in vitro RNA preparation to generate cleaner products 92 .
Guide RNA and donor DNA design tips: Guide RNA selection is a critical factor in achieving highly efficient on-target editing while minimizing the chances of off-target cleavage. To aid in guide selection, several studies have used high-throughput screens coupled with next-generation sequencing to compile sequence features of successful guides 47, 79, 93, 94, 95, 96 . These features have been used to develop predictive algorithms and online tools to assist in guide selection 44, 45, 46, 47, 48 . Such algorithms are grounded on screens using DNA-based systems for guide RNA expression. Guides are expressed using a Pol III promoter, and their expression is therefore prone to the limitations associated with Pol III transcription, such as premature termination when encountering tracks of uracil concerns and simplifies the constraints on guide design. A common feature that emerged from these algorithms and has been confirmed in numerous studies with highly effective genome editing, is the presence of a purine, particularly a guanine, at the 3′ end of the guide's targetspecific sequence. This guide feature has been very successful among organisms ranging from mammals to C. elegans, fruit flies, and zebrafish 65, 100, 101 . In addition, for C. elegans, designing guides with a GG dinucleotide at the 3′ end of the guide's targeting region is an effective strategy for predicting highly effective guide RNAs 65 . Ideally, test multiple guides in parallel to determine which is most successful for a given application.
When attempting to introduce a DNA sequence into the genome, the design of the donor or template DNA is also crucial. Single-stranded oligonucleotide donors (ssODNs) are inserted more reliably than other typical repair templates, linear double-stranded and plasmid DNA 54, 55, 102 . At some loci, HDR efficiency can be improved with ssODNs that are complementary to the non-target or displaced DNA strand and possess homology arms that are asymmetric in length 27, 55 . Since the repair template is being inserted at the cut site and includes the targeted sequence, steps must be taken to prevent Cas9 from cleaving the donor DNA before or after the genomic insertion. This is accomplished by making silent mutations to the PAM sequence or seed region, avoiding the recognition by Cas9 while retaining the function of the inserted gene 21, 103 . Though even single nucleotide changes to the PAM are likely to abolish binding 104 , try to change at least four nucleotides to be safe.
Significance and future applications:
Genome editing with CRISPR-Cas9 has emerged as a powerful method enabling facile genetic manipulation of any organism. Editing with the Cas9 RNP takes a bit more effort at first but is straightforward to use once reagents and protocols are established in a lab. Editing cells with preassembled RNP instead of plasmid DNA leads to higher overall editing efficiencies, including the difficult-to-achieve gene insertion via HDR, with fewer off-target effects 24, 25, 26, 27, 29 . Further, experimenters avoid problems with gene expression, RNA degradation, protein folding, and the association between gRNA and Cas9 molecules synthesized separately within the cell 22, 23 . RNP editing also circumvents safety concerns about insertional mutagenesis and sustained expression that may arise when viral delivery methods are used clinically 14 . Because of these advantages, many scientists conducting pre-clinical, proof-of-concept experiments favor RNP editing for human therapeutic applications. Both in vivo and ex vivo RNP-based genome editing approaches are in development to treat or even cure a variety of conditions, from genetic diseases like Duchenne muscular dystrophy 105 and sickle cell disease 27 to HIV 29 and cancer 11 . Interestingly, Cas9 RNP is increasingly employed as a delivery method for agricultural engineering because it enables 'DNA-free' editing of plants 33, 34, 36 .
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